The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Bortezomib Rowex 3.5 mg Powder for solution for injection

Rowex LtdPA0711/288/001

Main Information

Trade NameBortezomib Rowex 3.5 mg Powder for solution for injection
Active SubstancesBortezomib (as mannitol boronic ester)
Dosage FormPowder for solution for injection
Licence HolderRowex Ltd
Licence NumberPA0711/288/001

Group Information

ATC CodeL01XG01 bortezomib


License statusAuthorised
Licence Issued13/04/2018
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2)
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back